Roxithromycin

• Description:

  Roxithromycin (RU-28965) is an orally active semi-synthethic macrolide antibiotic. Roxithromycin inhibits protein biosynthesis in the elongation step by binding to 50S bacterial ribosome. Roxithromycin has antimicrobial, antiproliferative, anti-inflammatory, tumour vasculature inhibiting and lung injury ameliorating effects[1][2][3][4][5][6][7][8][9][10][11].

• Product Name Alternative:

  RU-28965

• UNSPSC:

  12352005

• Hazard Statement:

  H410

• Target:

  Antibiotic; Apoptosis; Bacterial; NF-κB; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis; MAPK/ERK Pathway; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/roxithromycin.html

• Purity:

  99.86

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

• Smiles:

  C[C@H]([C@H]([C@](O)(C[C@H](/C1=N\OCOCCOC)C)C)O[C@@](O[C@H](C)C[C@@H]2N(C)C)([H])[C@@H]2O)[C@]([C@H](C(O[C@@H]([C@@](O)([C@H](O)[C@H]1C)C)CC)=O)C)([H])O[C@@](O[C@@H](C)[C@@H]3O)([H])C[C@@]3(C)OC

• Molecular Formula:

  C41H76N2O15

• Molecular Weight:

  837.05

• Precautions:

  H410

• References & Citations:

  [6]Yatsunami J, et al. Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett. 1998 Sep 25;131 (2) :137-43. |[7]Ito T, et al. Roxithromycin inhibits chemokine-induced chemotaxis of Th1 and Th2 cells but regulatory T cells. J Dermatol Sci. 2009 Jun;54 (3) :185-91.|[8]Takahashi H, et al. Roxithromycin decreases ultraviolet B irradiation-induced reactive oxygen intermediates production and apoptosis of keratinocytes. J Dermatol Sci. 2004 Feb;34 (1) :25-33. |[9]Zhang X, et al. Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells. Acta Pharmacol Sin. 2021 Dec;42 (12) :2058-2068.|[10]Ueno S, et al. Roxithromycin inhibits constitutive activation of nuclear factor {kappa}B by diminishing oxidative stress in a rat model of hepatocellular carcinoma. Clin Cancer Res. 2005 Aug 1;11 (15) :5645-50. |[11]Ci X, et al. Short-term roxithromycin treatment attenuates airway inflammation via MAPK/NF-κB activation in a mouse model of allergic asthma. Inflamm Res. 2012 Jul;61 (7) :749-58. |[1]Duewelhenke N, et al. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agents Chemother. 2007 Jan;51 (1) :54-63.|[2]Takakusagi K, et al. Multimodal biopanning of T7 phage-displayed peptides reveals angiomotin as a potential receptor of the anti-angiogenic macrolide Roxithromycin. Eur J Med Chem. 2015 Jan 27;90:809-21. |[3]Yamazaki H, et al. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26 (11) :1053-7.|[4]Bertho G, et al. Transferred nuclear Overhauser effect study of macrolide-ribosome interactions: correlation between antibiotic activities and bound conformations. Bioorg Med Chem. 1998 Feb;6 (2) :209-21.|[5]Chantot JF, et al. Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo) . 1986 May;39 (5) :660-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  Macrolide

• CAS Number:

  [80214-83-1]